Human monkeypox outbreak: Epidemiological data and therapeutic potential of topical cidofovir in a prospective cohort study - 14/04/23
, Rafael Escudero-Tornero, MD a, Guillermo Servera-Negre, MD a, Jose I. Bernardino, MD, PhD b, Almudena Gutiérrez Arroyo, MD c, Marta Díaz-Menéndez, MD, PhD d, Jose Manuel Busto-Leis, MD a, Patricia Roces Álvarez, MD c, Pedro Herranz Pinto, MD, PhD e, Elena Sendagorta Cudos, MD, PhD eAbstract |
Background |
Human monkeypox has become increasingly frequent worldwide since the outbreak was first reported in May 2022.
Objectives |
As cidofovir is effective against vaccinia and other Orthopoxvirus diseases, we hypothesize that its topical use could be an effective treatment for monkeypox skin lesions, avoiding the adverse effects of systemic administration.
Methods |
We conducted a prospective study to collect data on the clinical and virologic course of patients with monkeypox. All patients were offered symptomatic treatment. They were also offered treatment with topical cidofovir on a compassionate use basis. Twelve patients received treatment with topical cidofovir 1%, while the others received only symptomatic treatment. Prospective visits were scheduled for the collection of clinical and virological data.
Results |
Lesions cleared quicker in the cidofovir-treated group (hazard ratio, 4.572; P = .0039). The median time to resolution was 12 (11.5-15) and 18 (16-21) days, respectively. On day 14, polymerase chain reaction-positive skin lesions were detected in 10% of the cidofovir sample, compared with 62.5% of the non-treated group (P = .019). Local adverse effects were frequent (50%), especially in the anogenital region. No systemic adverse effects were reported.
Limitations |
The study is not a clinical trial and lacks a placebo-controlled arm.
Discussion |
Topical cidofovir is a potentially relevant therapy in patients with skin lesions but mild systemic involvement. Reducing time to resolution could shorten isolation time and improve the cosmetic impact in areas such as the face.
Le texte complet de cet article est disponible en PDF.Key words : cidofovir, monkeypox, skin, topical
Abbreviations used : PCR, STD
Plan
| Funding sources: None. |
|
| IRB approval status: The study has received approval from the local ethics committee, which is available for submission to the journal. |
|
| Consent informed: Consent for the publication of recognizable patient photographs or other identifiable material has been obtained by the authors and are available for submission to the journal. |
|
| Reprints not available from the authors. |
Vol 88 - N° 5
P. 1074-1082 - mai 2023 Retour au numéro
Article précédent
- A dermatologic assessment of 101 mpox (monkeypox) cases from 13 countries during the 2022 outbreak: Skin lesion morphology, clinical course, and scarring
- Sonya Prasad, Cristina Galvan Casas, Alexis G. Strahan, L. Claire Fuller, Klint Peebles, Andrea Carugno, Kieron S. Leslie, Joanna L. Harp, Teodora Pumnea, Devon E. McMahon, Misha Rosenbach, Janet E. Lubov, Geoffrey Chen, Lindy P. Fox, Allen McMillen, Henry W. Lim, Alexander J. Stratigos, Terrence A. Cronin, Mark D. Kaufmann, George J. Hruza, Lars E. French, Esther E. Freeman
- Proteomic characterization of atopic dermatitis blood from infancy to adulthood
- Ester Del Duca, Yael Renert-Yuval, Ana B. Pavel, Daniela Mikhaylov, Jianni Wu, Rachel Lefferdink, Milie Fang, Anjani Sheth, Alli Blumstein, Paola Facheris, Yeriel D. Estrada, Stephanie M. Rangel, James G. Krueger, Amy S. Paller, Emma Guttman-Yassky
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?